RCT protocol for weekly rapamycin derivatives in older adults; results not yet reported
RAP PAC is a randomised trial designed to identify safe weekly doses of sirolimus or everolimus in adults aged 55-89 without overt chronic disease. Participants receive 6 weeks of treatment at 5, 10, or 15 mg once weekly. This is a protocol description; no efficacy or safety outcomes have been reported.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 28, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 4 months
- Population
- Participants aged 55-89 years old that are free of overt chronic diseases
- Primary outcome
- Not reported in abstract
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Wisconsin, Madison
- Published
- May 28, 2026
Sources
Primary source
- University of Wisconsin, Madison ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.